-
Product Insights
NewNet Present Value Model: Longeveron Inc’s Lomecel-B
Empower your strategies with our Net Present Value Model: Longeveron Inc's Lomecel-B report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lomecel-B in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lomecel-B in Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lomecel-B in Alzheimer's Disease Drug Details: Lomecel-B is under development for...
-
Product Insights
NewNet Present Value Model: Longeveron Inc’s Lomecel-B
Empower your strategies with our Net Present Value Model: Longeveron Inc's Lomecel-B report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Cefepime + Taniborbactam Hydrochloride) in Pyelonephritis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Cefepime + Taniborbactam Hydrochloride) in Pyelonephritis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Cefepime + Taniborbactam Hydrochloride) in Pyelonephritis Drug Details: Fixed dose...
-
Product Insights
NewCongenital Heart Disease – Drugs In Development, 2024
Empower your strategies with our Congenital Heart Disease – Drugs In Development, 2024 report and make more profitable business decisions. Congenital heart disease is an impairment of the heart’s structure that is present at birth. It may change the normal flow of blood through the heart. It is the most common type of birth defect, occurring in about 1% of live births in the US. There are different types of congenital heart defects; the most common involve the inside walls of...
-
Product Insights
NewNet Present Value Model: Novo Nordisk AS’s LAI-287 + Semaglutide
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pirtobrutinib in Chronic Lymphocytic Leukemia (CLL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pirtobrutinib in Chronic Lymphocytic Leukemia (CLL) Drug Details: Pirtobrutinib (Jaypirca) is an anti-neoplastic agent. It is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QR-0561 in Idiopathic Pulmonary Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QR-0561 in Idiopathic Pulmonary Fibrosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.QR-0561 in Idiopathic Pulmonary Fibrosis Drug Details: QR-0561 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lomecel-B in Ageing
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Lomecel-B in AgeingDrug Details:Lomecel-B is under development for the treatment of ageing frailty, hypoplastic left heart...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Invimestrocel in Traumatic Brain Injury
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Invimestrocel in Traumatic Brain Injury report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Invimestrocel in Traumatic Brain InjuryDrug Details:Invimestrocel (PF05285401) is under development for the...